QRxPharma Limited announced that the FDA has accepted its New Drug Application (NDA) for MoxDuo IR to treat moderate-to-severe acute pain. The FDA also set June 25, 2012 as the PDUFA (Prescription Drug User Fee Act) target date for action on the approval of the MoxDuo IR NDA.

MoxDuo IR comes in a capsule formulation in a 3:2 fixed ratio combination of morphine and oxycodone.  

For more information call (908) 506-2900 or visit www.qrxpharma.com.